SI1187612T1 - Use of riluzole for the treatment of multiple sclerosis - Google Patents

Use of riluzole for the treatment of multiple sclerosis

Info

Publication number
SI1187612T1
SI1187612T1 SI200030601T SI200030601T SI1187612T1 SI 1187612 T1 SI1187612 T1 SI 1187612T1 SI 200030601 T SI200030601 T SI 200030601T SI 200030601 T SI200030601 T SI 200030601T SI 1187612 T1 SI1187612 T1 SI 1187612T1
Authority
SI
Slovenia
Prior art keywords
riluzole
treatment
multiple sclerosis
benzothiazolamine
trifluoromethoxy
Prior art date
Application number
SI200030601T
Other languages
English (en)
Slovenian (sl)
Inventor
Chris Polman
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Publication of SI1187612T1 publication Critical patent/SI1187612T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI200030601T 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis SI1187612T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SI1187612T1 true SI1187612T1 (en) 2005-06-30

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030601T SI1187612T1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Country Status (11)

Country Link
EP (2) EP1552831B1 (enExample)
JP (1) JP2003522121A (enExample)
AT (2) ATE287713T1 (enExample)
AU (1) AU777537B2 (enExample)
CA (1) CA2375874A1 (enExample)
DE (1) DE60017733T2 (enExample)
ES (1) ES2235896T3 (enExample)
NZ (1) NZ515685A (enExample)
PT (1) PT1187612E (enExample)
SI (1) SI1187612T1 (enExample)
WO (1) WO2000074676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
BR112017010700A2 (pt) * 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
CN1202109A (zh) * 1995-11-15 1998-12-16 山之内制药株式会社 红藻氨酸神经细胞毒性抑制剂及吡啶并噻嗪衍生物
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose

Also Published As

Publication number Publication date
EP1552831A1 (en) 2005-07-13
ES2235896T3 (es) 2005-07-16
WO2000074676A1 (en) 2000-12-14
EP1187612A1 (en) 2002-03-20
ATE419851T1 (de) 2009-01-15
EP1552831B1 (en) 2009-01-07
ATE287713T1 (de) 2005-02-15
AU777537B2 (en) 2004-10-21
EP1187612B1 (en) 2005-01-26
AU5421900A (en) 2000-12-28
NZ515685A (en) 2002-12-20
PT1187612E (pt) 2005-05-31
CA2375874A1 (en) 2000-12-14
JP2003522121A (ja) 2003-07-22
DE60017733D1 (de) 2005-03-03
DE60017733T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
TWI256389B (en) Novel hPPAR delta agonists and pharmaceutical compositions comprising the same
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
IL162408A0 (en) Use of pramipexole to treat amyotrophic lateral scelrosis
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
SI1187612T1 (en) Use of riluzole for the treatment of multiple sclerosis
EP0681787A3 (en) Use of an enzyme for the manufacture of an agent suitable for the treatment and / or prophylaxis of coccidiosis.
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL152996A0 (en) Novel interferon for the treatment of multiple sclerosis
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases
AU2002365621A1 (en) Composition for treating the surface of the skin
ZA986090B (en) Agents for the prevention and/or treatment of radiation-induced disorders
EP1423125A4 (en) OESTROGENES NOT INDUCING FEMINIZATION AS PROTECTIVE AGENTS ON RETINA IN THE TREATMENT OF GLAUCOMA
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
EP1440165A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELL PROLIFERATION DISORDERS USING 25943